EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 5-May-2025 01:09 ET (5-May-2025 05:09 GMT/UTC)

Tumor DNA in the blood can predict lung cancer outcome

The Francis Crick Institute
Peer-Reviewed Publication

Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to detect circulating tumour DNA can predict lung cancer outcome in a Cancer Research UK-funded study.

Journal: Nature Medicine

CNIO and CNIC research identifies a key protein for ‘burning’ fat

Centro Nacional de Investigaciones Oncológicas (CNIO)
Peer-Reviewed Publication

This work reveals a new mechanism by which brown fat is converted into heat, and which protects from pathologies associated with obesity.

The MCJ protein is key to the fat burning mechanism now identified, making it a promising target for treating obesity, according to the authors in Nature Communications.

The research is led by Guadalupe Sabio, from Spain’s National Cancer Research Centre (CNIO), and Cintia Folgueira, from both CNIO and the National Centre for Cardiovascular Research (CNIC).

Journal: Nature Communications
Funder: “la Caixa” Foundation, Instituto de Salud Carlos III, Agencia Estatal de Investigación

Mystery solved: how tumor cells die after radiotherapy

Children's Medical Research Institute
Peer-Reviewed Publication

Scientists have struggled for decades to understand why radiation therapy kills cells from the same tumour in different ways. This is important because some forms of cell death are unnoticed by the immune system, while others trigger an immune response. Unleashing the patient’s immune system to clear tumours is a major goal of cancer treatment. This new research, published in Nature Cell Biology, reveals for the first time how DNA repair, which normally protects healthy cells, determines how cancer cells die following radiotherapy.

Journal: Nature Cell Biology
Funder: MRFF, Westmead Charitable Trust, Cancer Council NSW, Australian Cancer Research Foundation, National Health and Medical Research Council, National Health and Medical Research Council

Does obesity affect children’s likelihood of survival after being diagnosed with cancer?

Wiley
Peer-Reviewed Publication

A recent population-based study published by Wiley online in CANCER indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying.

Journal: Cancer

Advances and applications in single-cell and spatial genomics

Science China Press
Peer-Reviewed Publication

In a paper published in SCIENCE CHINA Life Science, an international team of scientists provided a comprehensive overview of single-cell and spatial genomics. They review breakthroughs in single-cell multi-omics technologies, spatial genomics methods, and the computational strategies employed toward the analyses of single-cell atlas data. Additionally, they emphasize the progress in constructing cellular atlases and their clinical applications, particularly in the context of disease. Lastly, they discuss emerging trends, challenges, and opportunities in this rapidly evolving field.

Journal: Science China Life Sciences

A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior

Baylor College of Medicine
Peer-Reviewed Publication

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators examined how molecular dynamics at the immune synapse – where CAR T cells bind to cancer cells – affect anticancer activity.

Journal: Science Advances

How many children use Tik Tok against the rules? Most, study finds

University of California - San Francisco
Peer-Reviewed Publication

Most 11- and 12-year-olds use Tik Tok and other social media despite the platforms’ age restrictions, and many show signs of addiction to social media, a new UC San Francisco study found.

Journal: Academic Pediatrics
Funder: NIH/National Institutes of Health, NIH/National Institutes of Health, Doris Duke Charitable Foundation

Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs

University of Colorado Anschutz Medical Campus
Peer-Reviewed Publication

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through Medicare Advantage received less expensive cancer drugs compared to others on Traditional Medicare.

The findings were published today in JAMA Health Forum.

"Lung cancer is the leading cause of cancer-related deaths in the United States and colorectal cancer ranks third. Gaining a better understanding of treatment options and their costs under different insurance plans is important for assessing the overall healthcare landscape and how insurances manage patient costs,” said the study’s first author Cathy Bradley, PhD, Dean of the Colorado School of Public Health.

The study found Medicare Advantage patients received less expensive cancer drugs, particularly for colorectal cancer, when compared to Traditional Medicare. But this was not the case for non-small cell lung cancer. The researchers found there are less low-cost treatment alternatives available, resulting in high-cost drugs regardless of insurance.

Journal: JAMA Health Forum

Intelligent fight: AI enhances cervical cancer detection

China Anti-Cancer Association
Peer-Reviewed Publication

A cutting-edge article is paving the way for a transformation in cervical cancer screening, leveraging artificial intelligence (AI) to enhance detection accuracy and efficiency.

Journal: Cancer Biology & Medicine

Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology

InSilico Medicine
Business Announcement

FLORENCE, Italy and CAMBRIDGE, Mass., January 10, 2025 : The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.